Skip to content
Inciteful Med

Standard of Care and Treatment Decisions

Last updated:

The standard first-line treatment for primary biliary cholangitis (PBC) is weight-based Ursodeoxycholic Acid (UDCA). If UDCA does not adequately lower liver enzymes after 12 months, second-line therapies like Seladelpar or Elafibranor can be added to protect the liver and relieve itching.

Key Takeaways

  • • UDCA is the foundational, lifelong treatment for PBC and must be correctly dosed based on your body weight.
  • • Doctors evaluate your response to UDCA after 12 months by checking alkaline phosphatase (ALP) and bilirubin levels.
  • • Newer second-line treatments like Seladelpar and Elafibranor can help lower liver enzymes and significantly reduce itching.
  • • Medications used for itching, like colestyramine, must be taken at least 4 hours apart from UDCA to avoid blocking its absorption.

Managing Primary Biliary Cholangitis (PBC) is a lifelong journey focused on two main goals: slowing the progression of liver damage and managing symptoms like itching and fatigue. Treatment is typically approached in a “stepwise” fashion, starting with a standard first-line therapy and adding or switching to other medications if needed [1][2].

First-Line Treatment: UDCA

The foundation of PBC care is Ursodeoxycholic Acid (UDCA). This is a naturally occurring bile acid that, when taken as a medication, helps move bile through the liver and protects liver cells from damage [3][4].

  • Dosing: To be effective, UDCA must be dosed correctly based on your weight, typically 13–15 mg/kg per day [3][5].
  • Duration: UDCA is a lifelong medication. Even if your lab results normalize, you must continue taking it to maintain liver protection [1].
  • The 12-Month Check: Doctors evaluate your response to UDCA between 6 and 12 months. An “inadequate response” is usually defined as an Alkaline Phosphatase (ALP) level that remains above 1.67 times the Upper Limit of Normal or a persistently elevated bilirubin level [6][7].

Second-Line Treatment Options

If UDCA does not sufficiently lower your liver enzymes, or if you cannot tolerate it, several second-line options are now available:

  1. PPAR Agonists (The “New Standard”): In 2024, the FDA approved two breakthrough medications, Seladelpar (Livdelzi) and Elafibranor (Iqirvo) [8][9]. These drugs work by targeting pathways that regulate bile acid production. Unlike older treatments, these have shown a significant ability to both lower liver enzymes and reduce itching [10][11].
  2. Obeticholic Acid (OCA): This medication (Ocaliva) is an FXR agonist that reduces bile acid synthesis [12]. While effective at lowering ALP, a common side effect is increased itching. Crucially, OCA carries a strict FDA Black Box Warning: it is strictly contraindicated and must not be used in patients with advanced or decompensated cirrhosis due to serious safety risks, including liver failure [12][13].
  3. Fibrates: Medications like bezafibrate are sometimes used “off-label” (without formal FDA approval for PBC) to help lower ALP and relieve itching [14][15].

Managing Debilitating Symptoms

Treating the underlying disease does not always immediately resolve symptoms. Specific medications can help manage the daily burden of PBC:

  • For Itching (Pruritus):
    • Colestyramine: Often the first choice, this medication “soaks up” bile acids in the gut [1][16]. Important: It must be taken at least 4 hours apart from your UDCA and other medications to avoid blocking their absorption. If taken together, it will bind to the UDCA and render your first-line treatment completely useless [16].
    • Rifampicin: An effective second-line option for severe itching, though it requires close monitoring of liver tests due to a risk of hepatotoxicity (liver injury) [17][1].
    • Naltrexone: An opioid antagonist that can help block the nerve signals causing the “itch” [18][19].
  • For Fatigue: Fatigue remains one of the hardest symptoms to treat. While medications like modafinil have been studied, they have not shown consistent success [20][21]. Managing sleep hygiene, addressing mental health, and ruling out other issues like vitamin deficiencies or thyroid problems is the current standard approach [22].
Treatment Goal Medication Options Key Consideration
Liver Protection UDCA (First-line) Must be weight-based (13-15mg/kg) [3]
Advanced Protection Seladelpar, Elafibranor Used if ALP remains high after 12 months [8]
Itch Relief Colestyramine, Rifampicin Must be spaced 4 hours from UDCA to avoid blocking it [16]

Frequently Asked Questions

What is the standard first-line treatment for primary biliary cholangitis?
The foundation of PBC care is Ursodeoxycholic Acid (UDCA). It is a lifelong medication that helps move bile through the liver and protects liver cells from damage. To be most effective, it must be dosed correctly based on your body weight.
How do doctors know if my UDCA treatment is working?
Doctors typically evaluate your response to UDCA between 6 and 12 months after starting the medication. They will run blood tests to check if your alkaline phosphatase (ALP) and bilirubin levels have sufficiently decreased.
What options are available if UDCA does not work for my PBC?
If UDCA does not lower your liver enzymes enough, doctors may add second-line treatments. Newer options include PPAR agonists like Seladelpar and Elafibranor, which can lower liver enzymes and help reduce itching. Another option is Obeticholic Acid, though it may increase itching.
How can I manage the severe itching caused by PBC?
Doctors often prescribe medications like colestyramine to help soak up bile acids in the gut and relieve itching. It is very important to take colestyramine at least 4 hours apart from UDCA so it does not block your primary liver treatment from working.
Are there new treatments for PBC that help with both liver damage and itching?
Yes, in 2024 the FDA approved new medications called Seladelpar and Elafibranor. Unlike some older treatments, these drugs have shown a significant ability to lower liver enzymes while also reducing the severe itching commonly associated with the disease.

Questions for Your Doctor

  • • Is my current dosage of UDCA calculated correctly based on my weight (13–15 mg/kg)?
  • • Looking at my labs from the last 12 months, do I meet the criteria for an 'inadequate response' based on my ALP and bilirubin levels?
  • • Since I am still experiencing significant itching, would I be a candidate for one of the newer treatments like Seladelpar (Livdelzi) or Elafibranor (Iqirvo)?
  • • If we consider Obeticholic Acid (OCA), how will we monitor for the risk of worsening my itching, and confirm my liver isn't too scarred to safely take it?
  • • If we start colestyramine for my itching, how exactly should I schedule it to ensure it doesn't block my UDCA?

Questions for You

  • • Have I been taking my UDCA consistently every day as prescribed?
  • • Has my itching improved, stayed the same, or worsened since I started my current treatment?
  • • On a scale of 1 to 10, how much is fatigue or itching currently impacting my ability to work or enjoy my hobbies?
  • • Am I experiencing any new side effects, such as digestive issues or skin changes, since starting my medications?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    [Primary biliary cholangitis-established and novel therapies].

    Vetter M, Kremer AE

    Der Internist 2018; (59(6)):544-550 doi:10.1007/s00108-018-0427-0.

    PMID: 29691599
  2. 2

    [Primary biliary cholangitis].

    Soret PA, Chazouillères O, Corpechot C

    La Revue du praticien 2021; (71(8)):885-891.

    PMID: 35147347
  3. 3

    [Diagnosis and Treatment of Primary Biliary Cholangitis].

    Kim KA

    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 2023; (81(2)):86-90 doi:10.4166/kjg.2023.002.

    PMID: 36824036
  4. 4

    Emerging Therapeutic Strategies in The Fight Against Primary Biliary Cholangitis.

    Medford A, Childs J, Little A, et al.

    Journal of clinical and translational hepatology 2023; (11(4)):949-957 doi:10.14218/JCTH.2022.00398.

    PMID: 37408803
  5. 5

    Clinical characteristics of newly diagnosed patients with primary biliary cholangitis (PBC) indicate the need for better awareness on timely diagnosis and adequate UDCA therapy.

    Stein K, Hofmann WP, Franke A, et al.

    Zeitschrift fur Gastroenterologie 2025; (63(12)):1260-1267 doi:10.1055/a-2721-1160.

    PMID: 41365315
  6. 6

    Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis.

    Roberts SB, Choi WJ, Worobetz L, et al.

    JHEP reports : innovation in hepatology 2024; (6(10)):101168 doi:10.1016/j.jhepr.2024.101168.

    PMID: 39380718
  7. 7

    High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: a retrospective cohort study.

    Zhu H, Zheng M, He H, et al.

    BMC gastroenterology 2023; (23(1)):400 doi:10.1186/s12876-023-03031-8.

    PMID: 37978445
  8. 8

    Seladelpar Improves Cholestasis and Pruritus in Obeticholic Acid and Fibrate-experienced Patients With Primary Biliary Cholangitis.

    Gordon SC, Proehl S, Pratt D, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2026; doi:10.1016/j.cgh.2026.01.011.

    PMID: 41577065
  9. 9

    Seladelpar: First Approval.

    Hoy SM

    Drugs 2024; (84(11)):1487-1495 doi:10.1007/s40265-024-02114-4.

    PMID: 39572508
  10. 10

    A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.

    Hirschfield GM, Bowlus CL, Mayo MJ, et al.

    The New England journal of medicine 2024; (390(9)):783-794 doi:10.1056/NEJMoa2312100.

    PMID: 38381664
  11. 11

    Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis.

    Kremer AE, Mayo MJ, Hirschfield GM, et al.

    Hepatology (Baltimore, Md.) 2024; (80(1)):27-37 doi:10.1097/HEP.0000000000000728.

    PMID: 38117036
  12. 12

    Obeticholic acid in primary biliary cholangitis: where we stand.

    Manne V, Kowdley KV

    Current opinion in gastroenterology 2019; (35(3)):191-196 doi:10.1097/MOG.0000000000000525.

    PMID: 30844895
  13. 13

    The treatment of primary biliary cholangitis: from shadow to light.

    Sylvia D, Tomas K, Marian M, et al.

    Therapeutic advances in gastroenterology 2024; (17()):17562848241265782 doi:10.1177/17562848241265782.

    PMID: 39081664
  14. 14

    Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis.

    Wang C, Shi Y, Wang X, et al.

    Frontiers in immunology 2022; (13()):940688 doi:10.3389/fimmu.2022.940688.

    PMID: 35880178
  15. 15

    Comparative effectiveness of peroxisome proliferator-activated receptor agonists as second-line therapies for primary biliary cholangitis: A systematic review and network meta-analysis.

    Martins A, Khakoo NS, Reddy A, et al.

    Hepatology (Baltimore, Md.) 2025; doi:10.1097/HEP.0000000000001465.

    PMID: 41052304
  16. 16

    Variation in microbiome and metabolites is associated with advantageous effects of cholestyramine on primary biliary cholangitis with pruritus.

    Zhou Y, Ying G, Shen W, et al.

    Microbiology spectrum 2026; (14(2)):e0074725 doi:10.1128/spectrum.00747-25.

    PMID: 41489381
  17. 17

    Comparison of Sertraline with Rifampin in the treatment of Cholestatic Pruritus: A Randomized Clinical Trial.

    Ataei S, Kord L, Larki A, et al.

    Reviews on recent clinical trials 2019; (14(3)):217-223 doi:10.2174/1574887114666190328130720.

    PMID: 30919782
  18. 18

    Pathogenesis and Management of Pruritus in PBC and PSC.

    Kremer AE, Namer B, Bolier R, et al.

    Digestive diseases (Basel, Switzerland) 2015; (33 Suppl 2()):164-75 doi:10.1159/000440829.

    PMID: 26641452
  19. 19

    Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review.

    Trivedi HD, Lizaola B, Tapper EB, Bonder A

    The American journal of medicine 2017; (130(6)):744.e1-744.e7 doi:10.1016/j.amjmed.2017.01.037.

    PMID: 28238692
  20. 20

    Managing cognitive symptoms and fatigue in cholestatic liver disease.

    Phaw NA, Leighton J, Dyson JK, Jones DE

    Expert review of gastroenterology & hepatology 2021; (15(3)):235-241 doi:10.1080/17474124.2021.1844565.

    PMID: 33131347
  21. 21

    A Randomized, Placebo-Controlled Clinical Trial of Efficacy and Safety: Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis.

    Silveira MG, Gossard AA, Stahler AC, et al.

    American journal of therapeutics 2017; (24(2)):e167-e176 doi:10.1097/MJT.0000000000000387.

    PMID: 27148676
  22. 22

    Anxiety and Depression in Patients with Primary Biliary Cholangitis: Current Insights and Impact on Quality of Life.

    Sivakumar T, Kowdley KV

    Hepatic medicine : evidence and research 2021; (13()):83-92 doi:10.2147/HMER.S256692.

    PMID: 34483690

This page explains primary biliary cholangitis (PBC) treatment options for educational purposes only. Always consult your hepatologist or gastroenterologist before starting or changing medications.

Stay up to date

Get notified when new research about Primary biliary cholangitis is published.

No spam. Unsubscribe anytime.